Refill Port Identification of Intrathecal Drug Delivery System Devices With a Raised Fill Port

被引:4
作者
Maino, Paolo [1 ]
van Kuijk, Sander M. J. [2 ]
Koetsier, Eva [1 ]
机构
[1] Reg Hosp Lugano, Neuroctr Southern Switzerland, Pain Management Ctr, Lugano, Switzerland
[2] Maastricht Univ, Med Ctr, Clin Epidemiol & Med Technol Assessment, Maastricht, Netherlands
关键词
intrathecal drug delivery; intrathecal pumps; chronic pain; spasticity; CONFERENCE PACC RECOMMENDATIONS; CLONIDINE OVERDOSE; MANAGEMENT; PREVENTION; THERAPY;
D O I
10.1111/papr.12759
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives The aim of this study was to assess the accuracy of the manual identification of the reservoir fill port (RFP) for refill of intrathecal drug delivery systems (IDDSs) with a raised RFP on the pump surface (raised-RFP-IDDSs), and compare this to previously reported data of patients with IDDSs with a recessed RFP (recessed-RFP-IDDSs). Methods Nineteen patients underwent 2 IDDS refills for the treatment of noncancer pain or spasticity. The primary endpoint of this prospective observational study was the deviation between the needle insertion point and the RFP center, quantified by fluoroscopic visualization. A distance surpassing that between the center and the margin of the RFP of 4 mm was considered a clinically relevant deviation. The results were compared with previously reported data of a patient cohort with recessed-RFP-IDDSs, and the differences were tested using Student's t-test. Results The mean deviation from the RFP center was 4.9 mm (standard deviation = 3.7). The RFP identification accuracy deviated more than the clinically relevant difference in 17 out of 35 instances (48.6%). The number of attempts and median procedural time was significantly correlated to the needle deviation. The mean deviations in the raised-RFP-IDDS cohort were consistently lower compared to the recessed-RFP-IDDS cohort (first refill procedure 4.0 vs. 8.5, P < 0.001; second procedure 5.9 vs. 8.1, P = 0.074). Conclusion The results of this study suggest that the manual localization of the RFP for raised-RFP-IDDSs is moderately accurate, and more accurate if compared to previously published accuracy of the template-guided technique for recessed-RFP-IDDSs.
引用
收藏
页码:418 / 425
页数:8
相关论文
共 48 条
  • [31] Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System
    Wykoff, Charles C.
    Zhou, Brenda
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2018, 49 (12) : 913 - 917
  • [32] Evaluation of intrathecal drug delivery system for intractable pain in advanced malignancies A prospective cohort study
    Zheng, Shuyue
    He, Liangliang
    Yang, Xiaohui
    Li, Xiuhua
    Yang, Zhanmin
    MEDICINE, 2017, 96 (11)
  • [33] Intrathecal morphine combined with ropivacaine induces spinal myoclonus in cancer patients with an implanted intrathecal drug delivery system Three case reports
    Guo, Xuejiao
    Li, Yunze
    Yang, Yixin
    Zhao, Yimin
    Guo, Jianguo
    Zhang, Yanfeng
    Peng, Zhiyou
    Feng, Zhiying
    MEDICINE, 2019, 98 (18)
  • [34] Recommendations for Reducing Infection in the Practice of Implanting Spinal Cord Stimulation and Intrathecal Drug Delivery Devices: A Physician's Playbook
    Deer, Timothy R.
    Provenzano, David A.
    PAIN PHYSICIAN, 2013, 16 (03) : E125 - E128
  • [35] Archway Randomized Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration
    Holekamp, Nancy M.
    Campochiaro, Peter A.
    Chang, Margaret A.
    Miller, Daniel
    Pieramici, Dante
    Adamis, Anthony P.
    Brittain, Christopher
    Evans, Erica
    Kaufman, Derrick
    Maass, Katie F.
    Patel, Shienal
    Ranade, Shrirang
    Singh, Natasha
    Barteselli, Giulio
    Regillo, Carl
    OPHTHALMOLOGY, 2022, 129 (03) : 295 - 307
  • [36] Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
    Wykoff, Charles C.
    Campochiaro, Peter A.
    Pieramici, Dante J.
    Khanani, Arshad M.
    Gune, Shamika
    Maia, Mauricio
    Kagedal, Matts
    Ding, Han Ting
    Maass, Katie F.
    OPHTHALMOLOGY AND THERAPY, 2022, 11 (05) : 1705 - 1717
  • [37] Efficacy of intrathecal drug delivery system for refractory cancer pain patients: A single tertiary medical center experience
    Lin, Chih-Peng
    Lin, Wen-Ying
    Lin, Feng-Sheng
    Lee, Yow-Shan
    Jeng, Chuen-Shin
    Sun, Wei-Zen
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2012, 111 (05) : 253 - 257
  • [38] The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia
    Sindt, Jill E.
    Larsen, Steven D.
    Dalley, Andrew P.
    Collier, Willem H.
    Brogan, Shane E.
    ANESTHESIA AND ANALGESIA, 2020, 131 (01) : 280 - 287
  • [39] Population Pharmacokinetics of Ranibizumab Delivered via the Port Delivery System Implanted in the Eye in Patients with Neovascular Age-Related Macular Degeneration
    Kagedal, Matts
    Alskar, Oskar
    Petersson, Klas
    Hanze, Eva
    Maia, Mauricio
    Lu, Tong
    Vakhavkar, Shweta
    Quartino, Angelica
    Willis, Jeffrey R.
    Jin, Jin Y.
    Maass, Katie F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (11) : 1210 - 1220
  • [40] Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema The Pagoda Randomized Clinical Trial
    Khanani, Arshad M.
    Campochiaro, Peter A.
    Graff, Jordan M.
    Marcus, Dennis M.
    Miller, Daniel
    Mittra, Robert A.
    Regillo, Carl
    Sheth, Veeral S.
    Bobbala, Ashwini
    Gune, Shamika
    Lin, Stephanie
    Quezada-Ruiz, Carlos
    Malhotra, Varun
    JAMA OPHTHALMOLOGY, 2025,